Darbepoetin alfa for anemia with myelodysplastic syndrome

References

• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23(30):7594-603
   PubMed Web of Science ®Google Scholar
• Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011;16(Suppl 3):35-42
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Weiss SR, Baer MR, et al. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res 2013;37(6):675-80
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer, Lyon, France), Editors 2008;2
   Google Scholar
• Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22(3):538-43
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-88
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65
   PubMed Web of Science ®Google Scholar
• Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59(3):425-33
   PubMedGoogle Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25(23):3503-10
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes–coping with ineffective hematopoiesis. N Engl J Med 2005;352(6):536-8
   PubMed Web of Science ®Google Scholar
• Gerds AT, Sekeres MA. Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. Leuk Lymphoma 2014;55(10):2221-2
   PubMed Web of Science ®Google Scholar
• Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86(1):268-76
   PubMed Web of Science ®Google Scholar
• Li X, Bryant CE, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 2004;80(2):140-5
   PubMedGoogle Scholar
• Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007;35(11):1739-46
   PubMed Web of Science ®Google Scholar
• Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012;120(16):3173-86
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451(7176):335-9
   PubMed Web of Science ®Google Scholar
• Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010;16(1):59-66
   PubMed Web of Science ®Google Scholar
• Caceres G, McGraw K, Yip BH, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci USA 2013;110(40):16127-32
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009;106(31):12974-9
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28(33):4996-5010
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116(20):4045-59
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013;11(7):838-74
   PubMed Web of Science ®Google Scholar
• Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother 2002;36(7-8):1183-92
   PubMedGoogle Scholar
• Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128(2):204-9
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12):3671-4
   PubMed Web of Science ®Google Scholar
• Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16(12):1921-7
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133(5):513-19
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142(3):379-93
   PubMed Web of Science ®Google Scholar
• Gotlib J, Lavori P, Quesada S, et al. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009;84(1):15-20
   PubMed Web of Science ®Google Scholar
• Oliva EN, Nobile F, Alimena G, et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010;51(6):1007-14
   PubMed Web of Science ®Google Scholar
• Villegas A, Arrizabalaga B, Fernandez-Lago C, et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 2011;27(5):951-60
   PubMed Web of Science ®Google Scholar
• Nilsson-Ehle H, Birgegard G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions. Eur J Haematol 2011;87(3):244-52
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013;92(5):621-31
   PubMed Web of Science ®Google Scholar
• Giraldo P, Nomdedeu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107(12):2807-16
   PubMedGoogle Scholar
• Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037-46
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group. (E1996). Blood 2009;114(12):2393-400
   PubMed Web of Science ®Google Scholar
• Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT01362140
   Google Scholar
• Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111(2):574-82
   PubMed Web of Science ®Google Scholar
• Jädersten M, Montgomery SM, Dybedal I, et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106(3):803-11
   PubMedGoogle Scholar
• Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87(7):527-36
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010;2010:330-7
   PubMedGoogle Scholar
• Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008;26(36):5943-9
   PubMedGoogle Scholar
• Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010;149(2):244-9
   PubMedGoogle Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99(2):344-51
   PubMed Web of Science ®Google Scholar
• Westers TM, Alhan C, Chamuleau ME, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010;115(9):1779-84
   PubMed Web of Science ®Google Scholar
• Santini V, Schemenau J, Levis A, et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 2013;122(13):2286-8
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12(10):1264-73
   PubMed Web of Science ®Google Scholar
• Smith SW, Sato M, Gore SD, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012;97(1):15-20
   PubMed Web of Science ®Google Scholar
• Backx B, Broeders L, Hoefsloot LH, et al. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia 1996;10(3):466-72
   PubMedGoogle Scholar
• Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115(4):706-15
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100(21):1542-51
   PubMedGoogle Scholar
• Steensma DP, Komrokji RS, Stone RM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer 2014;120(11):1670-6
   PubMed Web of Science ®Google Scholar
• Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS). Available from: https://clinicaltrials.gov/show/NCT01222195
   Google Scholar
• Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes. Available from: https://clinicaltrials.gov/ct2/show/NCT00398047
   Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27(11):1850-6
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29(18):2521-7
   PubMed Web of Science ®Google Scholar
• The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS). Available from: https://clinicaltrials.gov/ct2/show/NCT01566695
   Google Scholar
• Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET). Available from: https://clinicaltrials.gov/ct2/show/NCT01584531
   Google Scholar
• Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008;6(9):942-53
   PubMedGoogle Scholar
• Goldberg SL, Chen E, Sasane M, et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion 2012;52(10):2131-8
   PubMed Web of Science ®Google Scholar
• Arellano ML, Borthakur G, Berger M, et al. A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clin Lymphoma Myeloma Leuk 2014;14(6):534-9
   PubMedGoogle Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25
   PubMed Web of Science ®Google Scholar